Allogene Therapeutics: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 cents.
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) was upgraded by research analysts at Citizens Jmp from a “market ...
The fresh funds will be used to expand clinics, invest in AI-driven healthcare, and enhance patient engagement, strengthening ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday. The company’s shares ...
Bengaluru-based Allo Health raises INR 16 Cr in Pre-Series A round led by Zerodha's Rainmatter to expand clinic network and ...
March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for ...
In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...
Allo Health raises Rs. 16 crore to expand India’s largest sexual health ecosystem: Our Bureau, Bengaluru Wednesday, March 12, 2025, 17:45 Hrs [IST] Allo Health, India’s leadin ...
Sexual health and wellness startup Allo Health has raised Rs 16 crore in a pre-series A round led by Zerodha's Rainmatter, with participation from existing investors. The funds will be used to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback